Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthieu Delaye

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
Cancer Treatment Reviews|July 1, 2026
Antiangiogenic therapies in gastric cancer: future directions for 2026 and beyond: an UNICANCER gastrointestinal group (UCGI) perspectiveJudith Raimbourg, Meher Ben Abdelghani, Valerie Boige, et al.
JHEP Reports : Innovation in Hepatology|October 13, 2025
Young-onset biliary tract cancers: Characteristics, treatment patterns, and patient outcomesThomas Pudlarz, Anthony Turpin, Natalia Soledad Tissera, et al.
Drugs & Aging|May 15, 2025
Age Does not Affect the Efficacy of Antibody Drug Conjugates, But is Associated with High-Grade Adverse Events in Patients with Cancer Enrolled in Early Phase Clinical TrialsAna Vaz Ferreira, Matthieu Delaye, Arnaud Pages, et al.
Frontiers in Oncology|May 29, 2026
Predicting survival of patients treated with antibody-drug conjugates in early-phase clinical trials using AI-quantified 3D body composition on CT scansMatthieu Delaye, Littisha Lawrance, Younes Belkouchi, et al.
International Journal of Cancer|November 1, 2023
Pathogenic alterations in PIK3CA and KMT2C are frequent and independent prognostic factors in anal squamous cell carcinoma treated with salvage abdominoperineal resectionAbderaouf Hamza, Julien Masliah-Planchon, Cindy Neuzillet, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
Cancer Treatment Reviews|July 1, 2026
Antiangiogenic therapies in gastric cancer: future directions for 2026 and beyond: an UNICANCER gastrointestinal group (UCGI) perspectiveJudith Raimbourg, Meher Ben Abdelghani, Valerie Boige, et al.
JHEP Reports : Innovation in Hepatology|October 13, 2025
Young-onset biliary tract cancers: Characteristics, treatment patterns, and patient outcomesThomas Pudlarz, Anthony Turpin, Natalia Soledad Tissera, et al.
Drugs & Aging|May 15, 2025
Age Does not Affect the Efficacy of Antibody Drug Conjugates, But is Associated with High-Grade Adverse Events in Patients with Cancer Enrolled in Early Phase Clinical TrialsAna Vaz Ferreira, Matthieu Delaye, Arnaud Pages, et al.
Frontiers in Oncology|May 29, 2026
Predicting survival of patients treated with antibody-drug conjugates in early-phase clinical trials using AI-quantified 3D body composition on CT scansMatthieu Delaye, Littisha Lawrance, Younes Belkouchi, et al.
International Journal of Cancer|November 1, 2023
Pathogenic alterations in PIK3CA and KMT2C are frequent and independent prognostic factors in anal squamous cell carcinoma treated with salvage abdominoperineal resectionAbderaouf Hamza, Julien Masliah-Planchon, Cindy Neuzillet, et al.
Pageof 7